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Background. Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012, causing severe
acute respiratory disease and pneumonia, with 44% mortality among 136 cases to date. Design of vaccines to limit
the virus spread or diagnostic tests to track newly emerging strains requires knowledge of antigenic and serologic re-
lationships between MERS-CoV and other CoVs.
Methods. Using synthetic genomics and Venezuelan equine encephalitis virus replicons (VRPs) expressing
spike and nucleocapsid proteins from MERS-CoV and other human and bat CoVs, we characterize the antigenic re-
sponses (using Western blot and enzyme-linked immunosorbent assay) and serologic responses (using neutraliza-
tion assays) against 2 MERS-CoV isolates in comparison with those of other human and bat CoVs.
Results. Serologic and neutralization responses against the spike glycoprotein were primarily strain specific,
with a very low level of cross-reactivity within or across subgroups. CoV N proteins within but not across subgroups
share cross-reactive epitopes with MERS-CoV isolates. Our findings were validated using a convalescent-phase
serum specimen from a patient infected with MERS-CoV (NA 01) and human antiserum against SARS-CoV,
human CoV NL63, and human CoV OC43.
Conclusions. Vaccine design for emerging CoVs should involve chimeric spike protein containing neutralizing
epitopes from multiple virus strains across subgroups to reduce immune pathology, and a diagnostic platform
should include a panel of nucleocapsid and spike proteins from phylogenetically distinct CoVs.
Keywords. MERS-CoV Vaccine Design; Diagnostics; Serology; Synthetic Genomics.
Novel approaches are needed to respond rapidly to new
emerging diseases, especially early in the epidemic, when
prompt public health interventions can limit mortality
and epidemic spread. Coronaviruses (CoVs) constitute a
group of phylogenetically diverse enveloped viruses that
have the largest plus-strand RNA genomes and replicate
efficiently in most mammals [1, 2]. Human CoV (HCoV-
229E, -OC43, -NL63, and -HKU 1) infections typically
result in mild-to-severe upper and lower respiratory tract
disease [3, 4]. SARS-CoV emerged in 2002–2003, causing
acute respiratory distress syndrome with 10% mortality
overall and up to 50% mortality among aged individuals
[5]. Most recently, Middle East respiratory syndrome
CoV (MERS-CoV) emerged in the Middle East in April
2012, manifesting as severe pneumonia, acute respiratory
distress syndrome, and acute renal failure. The virus is
still circulating and has caused 136 human infections
with 58 deaths (mortality rate, approximately 44%) [6, 7].
Received 16 August 2013; accepted 11 October 2013; electronically published 18
November 2013.
aS. A. and R. G. contributed equally to this work.
Presented in part: MERS-CoV study group meeting June 20-22, 2013, Cairo, Egypt.
Correspondence: Ralph S. Baric, PhD, Department of Microbiology and Immunol-
ogy, 3304 Michael Hooker Research Bldg, Campus Box 7435, Chapel Hill, NC
27599-7435 (rbaric@email.unc.edu).
The Journal of Infectious Diseases 2014;209:995–1006
© The Author 2013. Published by Oxford University Press on behalf of the Infectious
Diseases Society of America. All rights reserved. For Permissions, please e-mail:
journals.permissions@oup.com.
DOI: 10.1093/infdis/jit609
MERS-CoV Serology and Vaccine Design • JID 2014:209 (1 April) • 995
Phylogenetic analysis groups CoVs into 4 genera—
Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and
Deltacoronavirus—and for many mammalian CoVs, bats are
considered reservoirs [6, 8, 9]. SARS-CoV is closely related to
bat CoV (BtCoV) HKU 3 [1, 10–12], whereas MERS-CoV is
closely related to Pipistrellus BtCoV HKU 5 and Tylonycteris
BtCoV HKU 4 [9]. However, the serologic and antigenic rela-
tionship between strains is unclear. Given the vast number of
genetically distinct CoVs, well-defined serologic and virologic
reagents are needed to rapidly track MERS-CoV and other CoV
infections in natural populations and to optimize vaccine and
therapeutic designs early in an outbreak setting, especially
within and between phylogenetic subgroups.
The spike (S) and nucleocapsid (N) proteins are major im-
munogenic components of CoVs and are produced in abun-
dant quantities during infection. The S protein is the principle
determinant of protective immunity and cross-species trans-
mission in CoV [11]. Antibodies against S protein protect from
homologous and heterologous SARS-CoV challenge in vivo
[13], whereas N protein–specific immune responses may offer
limited protection especially against low-dose challenge [13].
Therefore, antibodies against S and N protein have diagnostic
and therapeutic potential [14, 15].
In this article, we use alphavirus replicon vaccine vectors to
express a panel of recombinant S and N proteins from distantly
related alphacoronaviruses and betacoronaviruses, including
MERS-CoV and other subgroup 2c CoVs. Using mouse poly-
clonal antisera and recombinant proteins, we compare the
cross-reactivity and neutralization titers of these antisera
between distantly related human and bat CoVs. Our results in-
dicate that the S glycoprotein but not the N protein is the major
determinant of the neutralizing antibody response to MERS-
CoV; that the N proteins of CoVs only cross-react within but
not between subgroups; that little if any cross-neutralization or
cross-reactivity exists between the S proteins of CoVs within
subgroup 2c or any other subgroup; and that cross-neutraliza-
tion and cross-reactive patterns were validated with the conva-
lescent-phase serum sample from a patient infected with
MERS-CoV Hu/England-N1/2012 and a donor panel of
human antisera against 3 different HCoVs. Our approach pro-
vides critical reagents, antisera, and recombinant virus vaccines
that allow for rapid diagnosis of and intervention against
MERS-CoV and other zoonotic CoVs that emerge in the future.
MATERIALS ANDMETHODS
Viruses, Cells, and Plaque Assays
MERS-CoV Hu/England-N1/2012 and MERS-CoV Hu/SA-
N1/2012 were cultured on Vero 81 cells and grown in Opti-
Mem (Gibco, Carlsbad, CA) with 5% fetal clone serum
(Hyclone, South Logan, UT) and gentamicin/kanamycin
(Gibco). Viral growth assays in Vero and Calu-3 cells were per-
formed as previously described [16].
Generation of Polyclonal Mouse Antisera, Neutralization
Assays, and Western and Northern Blot Analysis
Genes encoding the indicated S and N proteins were synthe-
sized from Bio Basic (Ontario, Canada) and packaged into
Venezuelan equine encephalitis virus replicon particles (VRPs).
Following vaccination, mouse polyclonal sera were generated
from BALB/c mice, and neutralization assays involving MERS-
CoV strains and SARS-CoV were as described previously [17].
For Western blots, VRP or virus-infected cell lysates and con-
trols were prepared as described before in detail [8], and these
blots were probed using the indicated mouse polyclonal sera.
Vero cells inoculated with MERS-CoV isolates were harvested
12 hours after infection by means of Trizol reagent (Invitrogen)
and were used to perform Northern blots [18].
Enzyme-Linked Immunosorbent Assay (ELISA) and Blocking
Assay
An ELISA using indicated virus-infected cell lysates or antigens
expressed from VRPs was performed as described previously
[19], and the reactivity of mouse or human serum was deter-
mined using a chemiluminescent substrate. Blocking ELISA
was performed by sequentially reacting plate-bound MERS-
CoV lysate antigen with convalescent-phase serum obtained
from a patient with MERS, followed by mouse polyclonal
serum raised against VRP-packaged MERS-CoV N or S pro-
teins. Blocking was expressed as the percentage reduction in the
reactivity of the mouse serum alone.
RESULTS
Molecular Characterization of MERS-CoV Hu/England-N1/2012
MERS-CoV Hu/England-N1/2012 (MERS Eng 1) was isolated
from a 49-year-old patient with severe respiratory illness and
was transferred to London for treatment [7]. Twenty-nine mu-
tations in MERS Eng 1 at the amino acid level were identified
and compared to the published sequence of MERS-CoV Hu/
SA-N1/2012 (MERS SA 1; GenBank JX869059.2; Supplementa-
ry Figure S2). To identify whether these mutations altered virus
growth, we analyzed the replication kinetics of the 2 isolates in
Vero cells and a continuous epithelial cell line, Calu-3
(Figure 1A and 1B). Although the replication kinetics were
slightly different between 2 isolates in Vero cells, peak viral
titers were equivalent. In contrast, virus growth was markedly
distinct in human Calu-3 cells and could have represented dif-
ferences in strain-specific in vitro adaptation phenotypes or re-
sulted from functional differences in the sensitivity to innate
immune responses [20].
CoV replication and transcription involves production of a
nested set of subgenomic messenger RNAs (mRNAs) [2], and
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previous reports predicted 10 open reading frames in MERS SA
1 and MERS Eng 1 [9]. Northern blot analysis identified 8 sub-
genomic mRNAs after infection in both viruses (Figure 1C).
The observed nested set of subgenomic mRNA expression is
consistent with observations for other CoVs [2, 9]. The open
reading frames encoded by each mRNA in these isolates are de-
tailed in Supplementary Table 1.
Serologic Relationships Among MERS-CoV Strains
VRPs function as efficient expression and vaccine platforms for
a variety of antigens [13, 21]. We generated VRPs expressing
MERS SA 1 S and N proteins and then immunized mice.
N protein–specific antiserum recognized a discrete 50-kDa band
at the predicted molecular weight in lysates from Vero cells
(Supplementary Figure 1A) and Calu-3 cells (Figure 1D) infect-
ed with VRP-N or with the 2 different MERS-CoV isolates. For
the most part, similar expression patterns were evident between
VRPs and viruses; however, the N protein of MERS Eng 1 had
a slightly lower molecular weight, which was consistent with
amino acid deletions at positions S391 and I392 (Supplementa-
ry Figure 2).
Mouse anti-S serum identified an approximately 180-kDa S
protein in VRP-S– or MERS-CoV–infected Vero cells (Supple-
mentary Figure 1A). The observed molecular weights were con-
sistent with the sizes of the S proteins of other CoVs [2, 22].We
noted similar results in Calu-3 cells (Figure 1D), and interest-
ingly, an increased amount of a higher-molecular-weight form
of S protein (glycosylated dimer) was noted in MERS Eng 1 in
both cell lines. Antiserum against MERS SA 1 S and N proteins
also recognized MERS Eng 1 in ELISAs (data not shown), and
N and S proteins recognized the MERS-CoV Jordan isolate
(Supplementary Figure 1B).
Figure 1. Growth of Middle East respiratory syndrome coronavirus (MERS-CoV) Hu isolates at indicated multiplicity of infection (MOI) in Vero cells (A)
and Calu-3 cells (B). Infected cultures were sampled in triplicates at times indicated, and viral titers (shown as plaque-forming units [PFU]/mL) were deter-
mined by plaque assay on Vero cells. Error bars indicate standard error of the mean. C, Northern blot analysis of RNA harvested 12 hours after infection
from Vero cells infected with MERS-CoV Hu isolates at a MOI of 5. D, Western blots of lysates harvested 12 hours after infection from Calu-3 2B4 cells in-
fected with MERS-CoV Hu isolates at a MOI of 5 that were probed with antisera to spike (S) and nucleocapsid (N) proteins. β-actin indicates loading
control.
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Cross-neutralization Patterns Across Strains
Plaque reduction neutralization tests (PRNT50) indicated com-
plete neutralization of both MERS-CoV isolates (PRNT50 titer,
approximately 1:1400 for each; Figure 2A) and the MERS-CoV
Jordan isolate (Supplementary Figure1C) by VRP-S antiserum,
whereas no neutralization was observed with N antiserum.
Similar findings have been reported with SARS-CoV, as well as
with other known human and animal CoVs [13, 23]. Interesting-
ly, serum from aged mice vaccinated with VRP S showed a 6-fold
reduction in PRNT50 titers (approximately 1:200), indicating that
immunosenescence attenuates vaccine responses to MERS-CoV
antigens, as was noted with SARS-CoV vaccines [13, 17]. Using
serum from NA 01 patient, ELISA demonstrated high reactivity
of the patient’s serum to N and S antigens of MERS SA 1 ex-
pressed from VRPs (Figure 2B and 2C). Titers of antibody
against N protein in patient serum peaked 3–5 weeks after onset
of illness (which occurred on 3 September 2012) and waned
thereafter, but the antibodies were still detected up to 5 months
after illness onset. Titers of antibody against S protein were con-
sistent from 3 weeks to 5 weeks after illness onset, after which
they remained detectable. Most importantly, patient serum col-
lected on 16 November 2012 (which contained high titers against
S protein) outcompeted the binding of mouse S antiserum to
intact virus in a blocking assay (Figure 2D). These data suggest
that different/overlapping epitopes are recognized by human and
mouse antisera following virus or VRP-S infection.
Cross-reactive and Cross-neutralizing Antibody Responses
Within and Across Alphacoronaviruses and Betacoronaviruses
MERS SA 1 and MERS Eng 1 are closely related to BtCoV HKU
5 and BtCoV HKU 4 (Figure 2E) [6, 9, 24]. To evaluate antigenic
relationships with the subgroup 2c betacoronaviruses, VRPs ex-
pressing S and N proteins of BtCoV HKU 4.2 and BtCoV HKU
5.5 were inoculated into mice. Antisera against both HKU 4.2
and 5.5 N proteins recognized the N proteins of both MERS-
CoV isolates, whereas MERS SA 1 N antisera also detected the
VRP-expressed HKU 4.2 and 5.5 N proteins, as revealed by
Western blot (Figure 3A and 3B). We obtained similar results
using ELISA and immunofluorescence assays (data not shown).
In contrast, there was little if any observable cross-reactivity ob-
served between MERS SA 1 S antisera with the VRP-expressed S
proteins of HKU 4.2 and HKU 5.5, whereas antisera to HKU 5.5
S protein but not HKU 4.2 S protein recognized the S proteins of
both MERS-CoV isolates (Figure 3C and 3D). We also measured
serologic relationships using ELISA, which captures cross-reactiv-
ity to conformational epitopes, and confirmed these antigenic re-
lationships (Figure 6C). Consistent with results of serologic tests,
antisera against HKU 4.2 and HKU 5.5 S proteins did not cross-
neutralize the MERS-CoV isolates. These data indicate that the N
protein but not the S glycoprotein are antigenically conserved
within the subgroup 2c betacoronaviruses evaluated in this panel.
We then extended our analysis to the highly pathogenic
SARS-CoV and related subgroup 2b betacoronaviruses. Poly-
clonal mouse sera to SARS-CoV or MERS SA 1 N or S proteins
exhibited no cross-reactivity to the reciprocal strains (Figure 4A
and 4B). We observed very low levels of cross-neutralization of
MERS SA 1 by mouse antisera to SARS-CoV, using very high
but not low concentrations of serum (Figure 4C), a finding that
is consistent with a recent report [24]. Interestingly, ELISA
results also showed very minimal cross-reactivity of the NA 01
patient sera obtained on 23 September 2012 to SARS-CoV S
antigen (Figure 4D). Consistent with this observation, binding of
mouse SARS-CoV S antiserum to SARS-CoV was not inhibited
by NA01 patient sera in blocking assays (Figure 2D), indicating
the absence of antibodies to SARS-CoV in the patient serum.
Consonant with these findings, no cross-reactivity was ob-
served with antisera against the VRP-expressed N or S glyco-
proteins of BtCoV HKU 3 and 279 and the MERS-CoV isolates
(Figure 5A–D). Furthermore, no cross-neutralization of MERS-
CoV isolates by HKU 3S antiserum was observed, although this
serum has previously been shown to neutralize a synthetically
resurrected HKU 3 variant encoding the SARS S glycoprotein
receptor binding domain [23]. Interestingly, we observed very
low levels of cross-neutralization of SARS-CoV by BtCoV 279 S
antiserum (Figure 4C).
To further elucidate the antigenic relationships between the
S glycoproteins of alphacoronaviruses and the MERS-CoV iso-
lates, we expressed and generated mouse antisera to BtCoV 1A
and BtCoV HKU 2 (group 1b alphacoronaviruses), using the
VRP platforms. Despite efficient recombinant S glycoprotein
expression (Figure 7A and 7B), none of the recombinant S gly-
coproteins were recognized by MERS SA 1 S antisera. Antisera
against BtCoV1A and HKU 2 S glycoproteins had little if any
cross-reactivity with and did not neutralize MERS-CoV
(Figure 7A–C).
Antigenic Relationships Among the HCoVs
We next analyzed the antigenic relationships between VRP-
derived mouse serum with the following representative HCoVs
from each subgroup, using ELISA (Figure 6C): MERS Eng 1,
from subgroup 2c; SARS-CoV, from subgroup 2b; HCoV-NL63,
from subgroup 1b; and HCoV-OC43, from subgroup 2a. MERS
Eng 1 was recognized by antisera targeting the N but not the S
glycoprotein of viruses within the subgroup 2c betacoronaviruses.
Likewise, SARS-CoV was only recognized by antisera to N but
not S glycoproteins of viruses with the subgroup 2b betacoronavi-
ruses. None of the antiserum screened reacted with HCoV-NL63
(subgroup 1b) or HCoV-OC43 (subgroup 2a). Although BtCoV
HKU 2 is genetically close to HCoV-NL63, we did not observe
any cross-reactivity within the S glycoprotein.
Serum from patients infected with SARS-CoV, HCoV-NL63,
or HCoV-OC43 was screened against the N proteins from rep-
resentative subgroup 2c and 2d betacoronaviruses. Consistent
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Figure 2. A, Serum from each of 4 young and aged mice immunized with Venezuelan equine encephalitis virus replicons (VRPs) expressing spike (S) or
nucleocapsid (N) proteins were tested in a plaque reduction neutralization test to neutralize Middle East respiratory syndrome coronavirus (MERS-CoV) Hu
isolates. Error bars indicate standard error of the mean. B and C, NA01 patient sera collected at indicated dates after hospitalization were analyzed in an
enzyme-linked immunosorbent assay, using cell lysates expressing S and N antigens from VRPs. D, Indicated dilutions of NA01 patient sera collected on
November 16, 2012 were screened with 1:800 dilutions of mouse antisera to S, N, bat CoV (BtCoV) HKU 5.5 N, or SARS-CoV S in an in vitro competition
assay for binding to MERS-CoV or SARS-CoV. E, The full-length genome sequences of 51 CoVs were downloaded from GenBank or PATRIC, aligned with
ClustalX, and phylogenetically compared by maximum likelihood estimation, using 100 bootstraps. The tree shows that CoVs are divided into 3 distinct phy-
logenetic groups, defined as α, β, and γ. This taxonomic nomenclature replaced the former group 1, 2, and 3 designation, respectively. Classical subgroup
clusters are marked as 2a–2d for the β-CoVs and as 1a and 1b for the α-CoVs. The tree was generated using maximum likelihood estimation with the
PhyML package. The scale bar represents nucleotide substitutions. Only nodes with bootstrap support of >70% are labeled. Accession numbers and defini-
tions of various CoV strains will be provided upon request.
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with our previous findings, human serum to SARS-CoV recog-
nized BtCoV HKU 3N, BtCoV 279N, and SARS-CoV N (sub-
group 2b) but did not recognize N proteins from other
subgroups (Figure 6B). Similarly, there was no cross-reactivity
of the human antisera from HCoV-NL63 (subgroup 1b) and
HCoV-OC43 (subgroup 2a) infections with any of the viral an-
tigens within the panel. Serum collected from the patient in-
fected with MERS-CoV NA01 showed cross-reactive binding
only to BtCoV HKU 5.5 N (subgroup 2c), and little if any
cross-reactivity was noted outside the subgroup (Figure 6A),
apart from very low, transient cross-detection of BtCoV 279 N
and from cross-reactivity to SARS-CoV S and N recombinant
proteins on a single day (23 September 2012).
DISCUSSION
Emerging respiratory CoVs offer a considerable threat to the
health of global populations and the economy. Platforms for
generating well-characterized molecular reagents and recombi-
nant viruses are needed to detect and control the emergence of
Figure 3. Western Blots showing cross-reactivity between nucleocapsid (N; A and B) and spike (S; C and D) proteins of Middle East respiratory syn-
drome coronavirus (MERS-CoV) Hu isolates and N and S proteins of bat CoV (BtCoV) HKU 4.2 and HKU 5.5 (E ). Plaque reduction neutralization tests
showing absence of cross-neutralization of MERS-CoV Hu isolates by antisera to BtCoV HKU 4.2 and 5.5 S proteins. Serum from groups of 4 mice immu-
nized with Venezuelan equine encephalitis virus replicons was tested in this assay. Error bars indicate standard error of the mean. Note the cross-reactivity
of antisera to BtCoV HKU 5.5 S protein to S proteins of MERS-CoV Hu isolates (D) but the absence of cross-neutralization.
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new strains, especially early in an outbreak, before the develop-
ment of type-specific serologic reagents and therapeutics. Here,
we characterized the genome organization, subgenomic mRNA
expression, and protein expression patterns of 2 isolates of
MERS-CoV. Using alphavirus replicon particles and synthetic
gene design, we assembled a panel of recombinant proteins
from and donor antisera against phylogenetically distant alpha-
coronaviruses and betacoronaviruses to evaluate the antigenic
relationships between strains and to inform vaccine design.
MERS-CoV is a highly pathogenic respiratory CoV of humans,
causing acute respiratory distress syndrome, with mortality
rates approaching 44%. CoV primer sets were not successful in
diagnosing the etiology of the Jordan outbreak in April 2012,
demonstrating a critical need for paneled reagent sets of recom-
binant proteins and sera that allow for serologic evaluations of
cases, contact cases, and asymptomatic infections, using
Western blot or ELISA-based techniques [25]. This article is
also the first report that describes the serologic characterization
of MERS-CoV and CoV reagents. An advantage of the VRP
platform is that it can also function as a vaccine vector,
affording the rapid production of candidate vaccines against
newly emerged strains [23]. Using SARS-CoV and MERS-CoV
as models, we clearly demonstrated that S protein–based re-
combinant vaccines elicit robust neutralization responses in
young and aged rodent models. Because VRP-S vectors against
SARS-CoV protected young and aged animals [17], we have de-
veloped a recombinant S vectored vaccine that could likely
prove successful in preventing heterologous MERS-CoV infec-
tion in aged individuals, but this remains to be tested.
MERS Eng 1 replicated to lower titers than SA1 in Calu-3
cells. As the 2 viruses have different passage histories in vitro,
tissue culture adaptive mutations may account for these differ-
ences, as reported with many SARS-CoV isolates [26]. Alterna-
tively, 29 amino acid differences have been described, most of
which reside in the replicase polyprotein (Supplementary
Figure 2) and may affect replication efficiency. In addition, the
S glycoprotein of MERS Eng 1 differs from that of MERS SA 1
by 2 amino acids, L506F and Q1020H (Supplementary
Figure 2), which may account for the increased amount of the
higher-molecular-weight form of S protein in MERS Eng 1
Figure 4. Western Blots showing no cross-reactivity between nucleocapsid (N; A) and spike (S; B) proteins of Middle East respiratory syndrome corona-
virus (MERS-CoV) Hu isolates and SARS-CoV. C, Plaque reduction neutralization tests showing the absence of cross-neutralization of MERS-CoV Hu
isolates by antisera to SARS-CoV S and of SARS-CoV by antisera to MERS-CoV/SA-1/2012 S protein and BtCoV 279 S protein. Note that antisera to SARS-
CoV S neutralize SARS-CoV. Serum from groups of 4 mice immunized with Venezuelan equine encephalitis virus replicons was tested in this assay and
error bars indicate standard error of the mean. D, Enzyme-linked immunosorbent assay results showing the absence of reactivity of NA01 patient sera to
SARS-CoV S antigen.
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(Figure 1D and Supplementary Figure 1A). Recent studies indi-
cate that TMPRSS2 likely plays important roles in viral entry by
enhancing fusogenic potential through proteolytic processing
of MERS-CoV S glycoprotein [22]. In addition, we identified a
unique mutation, T1015N, in the MERS SA 1 isolate but not in
the MERS Eng 1 isolate and showed that this mutation is re-
sponsible for increased in vitro fitness and for plaque morphol-
ogy [20]. It is possible that the presence or absence of 1 or more
of the S glycoprotein mutations in MERS Eng 1 may result in
the slower growth phenotype in Calu3 cells.
Alphavirus VRPs have considerable potential as recombinant
virus vaccine platforms in the absence of preexisting immunity
[27–30]. We demonstrate efficient expression of several CoV S
and N structural proteins both in vitro and in vivo, resulting in
robust serologic responses in vaccinated mice. Antiserum to
VRP-S glycoprotein but not to VRP-N protein neutralized both
isolates of MERS-CoV. Furthermore, we and others have dem-
onstrated that vaccine-induced immunopathology observed
after challenge is minimized in VRP-S protein–based vaccines,
partly because of the T-helper type 1–biased immune response
Figure 5. Western blots showing cross-reactivity between nucleocapsid (N; A and B) and spike (S; C and D) proteins of Middle East respiratory syndrome
coronavirus (MERS-CoV) Hu isolates and N and S proteins of BtCoV 279 and HKU 3. E, Plaque reduction neutralization tests showing absence of cross-
neutralization of MERS-CoV Hu isolates by antisera to BtCoV 279S and HKU 3 S proteins. Serum from groups of 4 mice immunized with Venezuelan equine
encephalitis virus replicons was tested in this assay. Error bars indicate standard error of the mean.
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and high neutralization titers elicited by VRP vectors [13, 31].
Importantly, vaccination of aged mice demonstrated that im-
munosenescence contributes to a reduction in the magnitude
of the antibody response to MERS-CoV S glycoprotein, an im-
portant point to be considered in candidate vaccine designs. To
date, wild-type and VRP 3526–coated VRP-S vaccines repre-
sent one of the few vaccine platforms that functioned well in
aged animals, in addition to recombinant subunit–based vac-
cines and poxvirus-vectored vaccines [21, 32–34]. In SARS-
CoV pathogenesis, increased age-related susceptibility is linked
to increased prostaglandin D2 expression; it remains uncertain
whether increased prostaglandin D2 levels have contributed to
reduced vaccine performance, as well [35]. Because we have not
observed MERS-CoV replication in immunocompetent and
immunocompromised mice, these vectors must be tested di-
rectly in primates [36]. The safety of the VRP platform has
been demonstrated in high-risk human populations and
immunosenescent nonhuman primates [27, 28, 37, 38], and we
believe that these vectors will be efficacious in healthcare
workers and target populations infected with MERS-CoV.
Our results indicate the presence of strongly cross-reactive
epitopes in the N protein within a particular subgroup but not
between subgroups. Under identical conditions, little cross-re-
activity or conservation of cross-neutralizing epitopes was ob-
served between S proteins within and across subgroups. Similar
studies showing strong conservation of cross-reactive epitopes
between N proteins, but to a lesser extent between S proteins of
the subgroup 2a CoVs, has been reported [39, 40]. Importantly,
the pattern of serologic and antigenic relationship observed
using the mouse antisera was recapitulated using the human
antiserum to 4 different CoVs. Neutralization assays demon-
strated little if any conservation of cross-neutralizing epitopes
between S glycoproteins of CoVs within and across subgroups.
In particular, the absence of cross-neutralization of MERS-CoV
Figure 6. A, NA01 patient serum specimens collected at indicated dates were analyzed in an enzyme-linked immunosorbent assay (ELISA), using cell
lysates expressing indicated antigens. B, Mouse antisera to the indicated antigens were screened in an ELISA. C, Human antisera to indicated CoVs were
screened in an ELISA with cell lysates expressing indicated antigens.
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isolates by antiserum to HKU 4 or HKU 5 S glycoprotein and
of SARS-CoV by antiserum to the HKU 3 or BtCoV 279 S gly-
coprotein suggests very limited conservation or, possibly, the
deliberate masking of conserved cross-neutralizing sites within
a subgroup. Although speculative, these cross-neutralization re-
lationships suggest that at least 3 antigenically distinct CoVs
could emerge from zoonotic viruses circulating within sub-
group 1a/b, 2b, and 2c reservoirs and then simultaneously cir-
culate in humans. These findings are evidence that vaccine
design for any new emerging CoV should either focus on the
development of chimeric S glycoproteins containing neutraliz-
ing epitopes from multiple strains within or across subgroups
or on the development of new paradigms in structure-guided
antigen design that improve the presentation of broadly neu-
tralizing epitopes. Regions of S glycoprotein are interchange-
able between CoVs within and across subgroups, rendering
viable recombinant viruses [23]. Inclusion of N protein in such
chimeric vaccines may broaden the protective response,
although this remains to be tested using lethal challenge
viruses. Such a vaccine might provide robust protection against
several homologous and heterologous viruses within or across
genoclusters.
After the SARS-CoV epidemic and in stark contrast to the
situation with emerging influenza viruses such as influenza A
(H7N9), the research and biomedical communities failed to
develop broadly applicable biopreparedness platforms for rapid
response against future emerging CoV threats. Because CoVs
have demonstrated an accelerating pattern of zoonotic emer-
gence since the 1980s [25, 41], our data indicate that an appro-
priate diagnostic platform should include a large panel of
phylogenetically distinct CoV S and N structural proteins,
which must be validated using larger panels of antisera against
other HCoVs in the general population. While molecular-
based platforms like polymerase chain reaction and deep se-
quencing offer clear advantages in early detection of active
infections, public health response platforms would be
Figure 7. Western blots showing the cross-reactivity of spike (S) proteins of bat coronavirus (BtCoV) HKU 2.298 (A) and BtCoV 1A (B) with Middle East
respiratory syndrome coronavirus (MERS-CoV) Hu isolates. C, Plaque reduction neutralization tests showing the absence of cross-neutralization of MERS-
CoV Hu isolates by antisera. Serum from groups of 4 mice immunized with Venezuelan equine encephalitis virus replicons was tested in this assay. Error
bars indicate standard error of the mean.
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strengthened by the availability of recombinant proteins and
subgroup- and type-specific antisera that can track subclinical
infections, determine the prevalence of infection in popula-
tions, and identify hospital-acquired infections. A recent report
identified subclinical cases of MERS-CoV infection through
reverse-transcription polymerase chain reaction, and the screen
using the panel of recombinant proteins described here would
have provided more-specific information about the presence of
other CoVs in these cases [42]. The VRP platform we describe
not only yields high-level expression of key recombinant pro-
teins across the alphacoronaviruses and betacoronaviruses, it
also provides the first candidate vaccine vectors with the poten-
tial to augment the T-helper type 1–based immune responses
to MERS-CoV infection and to reduce associated immune pa-
thology. The VRP 3526–associated approach is also applicable
to improving the public health response to and the control of
future outbreaks of other highly pathogenic emerging infec-
tious diseases due to CoV in human populations.
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